Loading...
XNAS
BLFS
Market cap1.06bUSD
Jul 24, Last price  
22.26USD
1D
-0.85%
1Q
-10.80%
Jan 2017
1,282.35%
Name

BioLife Solutions Inc

Chart & Performance

D1W1MN
P/E
P/S
12.95
EPS
Div Yield, %
Shrs. gr., 5y
18.81%
Rev. gr., 5y
24.62%
Revenues
82m
-42.59%
614,718603,219972,2621,322,4971,581,6002,081,5652,758,7295,662,9908,949,4016,190,6986,448,9108,227,00011,022,00019,742,00027,371,00048,087,000119,156,000161,759,000143,271,00082,254,000
Net income
-20m
L-69.61%
-619,323-1,134,018-2,851,774-2,775,117-2,768,352-1,983,630-1,956,639-1,659,586-1,084,160-3,217,750-4,213,936-6,875,000-2,515,0003,266,00011,062,0002,667,000-8,383,000-139,805,000-66,427,000-20,184,000
CFO
8m
P
-576,333-712,196-2,708,979-2,113,418-2,413,642-1,252,526-989,917854,934146,007-3,162,316-4,973,861-4,327,000605,0002,348,0001,213,0006,515,000-4,836,000-8,489,000-12,498,0008,431,000
Earnings
Aug 06, 2025

Profile

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
IPO date
Nov 22, 1989
Employees
466
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
82,254
-42.59%
143,271
-11.43%
161,759
35.75%
Cost of revenue
82,565
195,623
191,975
Unusual Expense (Income)
NOPBT
(311)
(52,352)
(30,216)
NOPBT Margin
Operating Taxes
(38)
169
(5,022)
Tax Rate
NOPAT
(273)
(52,521)
(25,194)
Net income
(20,184)
-69.61%
(66,427)
-52.49%
(139,805)
1,567.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,244
(131)
BB yield
-1.44%
0.02%
Debt
Debt current
12,454
13,179
4,832
Long-term debt
26,957
50,232
56,987
Deferred revenue
Other long-term liabilities
4,997
2,328
Net debt
(66,168)
6,099
(8,647)
Cash flow
Cash from operating activities
8,431
(12,498)
(8,489)
CAPEX
(3,227)
(6,381)
(10,385)
Cash from investing activities
58,300
17,837
(58,117)
Cash from financing activities
(6,783)
10,591
16,317
FCF
33,347
11,627
(18,196)
Balance
Cash
104,584
51,695
64,065
Long term investments
995
5,617
6,401
Excess cash
101,466
50,148
62,378
Stockholders' equity
(313,642)
(247,551)
Invested Capital
379,083
697,169
41,551
ROIC
ROCE
EV
Common stock shares outstanding
46,067
43,719
42,481
Price
25.96
59.75%
16.25
-10.71%
18.20
-51.17%
Market cap
1,195,901
68.33%
710,437
-8.11%
773,155
-46.12%
EV
1,129,733
716,536
764,508
EBITDA
8,350
(40,057)
(13,744)
EV/EBITDA
135.30
Interest
1,812
687
Interest/NOPBT